Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression

Journal of Clinical Investigation

Volumn 126, Issue 10, 2016, Pages 4045-4060

  Khattar, Ekta ^a   Kumar, Pavanish ^b,j   Liu, Chia Yi ^a   Can Akincilar, Semih ^a   Raju, Anandhkumar ^a   Lakshmanan, Manikandan ^a   Maury, Julien Jean Pierre ^a   Qiang, Yu ^c   Li, Shang ^d   Tan, Ern Yu ^e   Hui, Kam M ^a,d,f,g   Shi, Ming ^h   Loh, Yuin Han ^a   Tergaonkar, Vinay ^a,i  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e TAN TOCK SENG HOSPITAL   (Singapore)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

ⁱ UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^j Singapore Health Services   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED RNA POLYMERASE III; RPC32 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFER RNA; UNCLASSIFIED DRUG; POLR3G PROTEIN, HUMAN; PROTEIN BINDING; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CATALYSIS; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; MOUSE; NONHUMAN; ONCOGENE; POLYOMAVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; TELOMERE LENGTH; 129 MOUSE; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL TRANSFORMATION; ENZYMOLOGY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN DOMAIN; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RNA POLYMERASE III; RNA, TRANSFER; TELOMERASE;

EID: 84991628168     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86042     Document Type: Article

References (88)

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-460.
2. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66(3):407-425.
3. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007;447(7147):924-931.
4. Stewart SA, Weinberg RA. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol. 2006;22:531-557.
5. Gilson E, Geli V. How telomeres are replicated. Nat Rev Mol Cell Biol. 2007;8(10):825-838.
6. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6(8):611-622.
7. Liu Y, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol. 2000;10(22):1459-1462.
8. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13(17):1549-1556.
9. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614-636.
10. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426-434.
11. Cukusić A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res. 2008;122(3-4):263-272.
12. Vinagre J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.
13. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30-37.
14. Heidenreich B, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5:3401.
15. Horn S, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-961.
16. Gartner JJ, et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A. 2013;110(33):13481-13486.
17. Li Y, et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol. 2015;17(10):1327-1338.
18. Anic GM, et al. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol. 2013;37(4):434-439.
19. Liang G, Qureshi AA, Guo Q, De Vivo I, Han J. No association between telomere length in peripheral blood leukocytes and the risk of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1043-1045.
20. Li Y, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerasetargeted cancer therapies. Cancer Res. 2014;74(6):1639-1644.
21. Zhang X, Li B, de Jonge N, Bjorkholm M, Xu D. The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression. Oncotarget. 2015;6(7):4888-4900.
22. Yu ST, Chen L, Wang HJ, Tang XD, Fang DC, Yang SM. hTERT promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol. 2009;35(2):329-336.
23. Sato N, et al. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer. 2001;91(3):496-504.
24. Ghosh A, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012;14(12):1270-1281.
25. Choi J, et al. TERT promotes epithelial proliferation through transcriptional control of a Mycand Wnt-related developmental program. PLoS Genet. 2008;4(1):e10.
26. Allory Y, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65(2):360-366.
27. Yan P, Benhattar J, Coindre JM, Guillou L. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer. 2002;98(6):851-856.
28. Liu R, Iadevaia V, Averous J, Taylor PM, Zhang Z, Proud CG. Impairing the production of ribosomal RNA activates mammalian target of rapamycin complex 1 signalling and downstream translation factors. Nucleic Acids Res. 2014;42(8):5083-5096.
29. Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol. 2010;50:131-156.
30. Mayer C, Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene. 2006;25(48):6384-6391.
31. Gonzalez OG, et al. Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions. Nat Commun. 2014;5:4599.
32. Akincilar SC, et al. Quantitative assessment of telomerase components in cancer cell lines. FEBS Lett. 2015;589(9):974-984.
33. Xi L, Cech TR. Inventory of telomerase components in human cells reveals multiple subpopulations of hTR and hTERT. Nucleic Acids Res. 2014;42(13):8565-8577.
34. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 2001;29(23):4818-4825.
35. Topisirovic I, Sonenberg N. Distinctive tRNA repertoires in proliferating versus differentiating cells. Cell. 2014;158(6):1238-1239.
36. Yang JH, Shao P, Zhou H, Chen YQ, Qu LH. deepBase: a database for deeply annotating and mining deep sequencing data. Nucleic Acids Res. 2010;38(Database issue):D123-D130.
37. Pavon-Eternod M, Gomes S, Geslain R, Dai Q, Rosner MR, Pan T. tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res. 2009;37(21):7268-7280.
38. Kutter C, et al. Pol III binding in six mammals shows conservation among amino acid isotypes despite divergence among tRNA genes. Nat Genet. 2011;43(10):948-955.
39. Kenneth NS, Marshall L, White RJ. Recruitment of RNA polymerase III in vivo. Nucleic Acids Res. 2008;36(11):3757-3764.
40. Koh CM, et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest. 2015;125(5):2109-2122.
41. Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003;421(6920):290-294.
42. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell. 2011;44(4):667-678.
43. Haurie V, et al. Two isoforms of human RNA polymerase III with specific functions in cell growth and transformation. Proc Natl Acad Sci U S A. 2010;107(9):4176-4181.
44. Wong RC, et al. A novel role for an RNA polymerase III subunit POLR3G in regulating pluripotency in human embryonic stem cells. Stem Cells. 2011;29(10):1517-1527.
45. Gingold H, et al. A dual program for translation regulation in cellular proliferation and differentiation. Cell. 2014;158(6):1281-1292.
46. Oler AJ, et al. Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. Nat Struct Mol Biol. 2010;17(5):620-628.
47. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18(2):173-179.
48. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954-961.
49. Jaskelioff M, et al. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene. 2009;28(48):4225-4236.
50. Blasco MA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91(1):25-34.
51. Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res. 2001;3(3):146-149.
52. Holysz H, Lipinska N, Paszel-Jaworska A, Rubis B. Telomerase as a useful target in cancer fighting -the breast cancer case. Tumour Biol. 2013;34(3):1371-1380.
53. Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK. Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. Mol Cancer Res. 2005;3(9):503-509.
54. Bertorelle R, Rampazzo E, Pucciarelli S, Nitti D, De Rossi A. Telomeres, telomerase and colorectal cancer. World J Gastroenterol. 2014;20(8):1940-1950.
55. Gertler R, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22(10):1807-1814.
56. Toshikuni N, et al. Expression of telomeraseassociated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer. 2000;82(4):833-837.
57. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012;18(1):41-51.
58. White RJ. Transcription by RNA polymerase III: more complex than we thought. Nat Rev Genet. 2011;12(7):459-463.
59. Raina M, Ibba M. tRNAs as regulators of biological processes. Front Genet. 2014;5:171.
60. Mei Y, et al. tRNA binds to cytochrome c and inhibits caspase activation. Mol Cell. 2010;37(5):668-678.
61. Zhou Y, Goodenbour JM, Godley LA, Wickrema A, Pan T. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem Biophys Res Commun. 2009;385(2):160-164.
62. Zheng G, et al. Efficient and quantitative high-throughput tRNA sequencing. Nat Methods. 2015;12(9):835-837.
63. Cabarcas S, Schramm L. RNA polymerase III transcription in cancer: the BRF2 connection. Mol Cancer. 2011;10:47.
64. Winter AG, et al. RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors. Proc Natl Acad Sci U S A. 2000;97(23):12619-12624.
65. Marshall L, White RJ. Non-coding RNA production by RNA polymerase III is implicated in cancer. Nat Rev Cancer. 2008;8(12):911-914.
66. Strong MA, Vidal-Cardenas SL, Karim B, Yu H, Guo N, Greider CW. Phenotypes in mTERT+/-and mTERT-/-mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Mol Cell Biol. 2011;31(12):2369-2379.
67. Mukherjee S, Firpo EJ, Wang Y, Roberts JM. Separation of telomerase functions by reverse genetics. Proc Natl Acad Sci U S A. 2011;108(50):E1363-E1371.
68. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 2002;21(20):3130-3138.
69. Hahn WC, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5(10):1164-1170.
70. Liu H, Liu Q, Ge Y, Zhao Q, Zheng X, Zhao Y. hTERT promotes cell adhesion and migration independent of telomerase activity. Sci Rep. 2016;6:22886.
71. Beck S, et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells. 2011;31(1):9-15.
72. Listerman I, Sun J, Gazzaniga FS, Lukas JL, Blackburn EH. The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis. Cancer Res. 2013;73(9):2817-2828.
73. Zeller KI, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A. 2006;103(47):17834-17839.
74. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4(10):R69.
75. Raha D, et al. Close association of RNA polymerase II and many transcription factors with Pol III genes. Proc Natl Acad Sci U S A. 2010;107(8):3639-3644.
76. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015;4:e07198.
77. Armstrong L, et al. Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells. 2005;23(4):516-529.
78. Barski A, et al. Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes. Nat Struct Mol Biol. 2010;17(5):629-634.
79. Moqtaderi Z, et al. Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. Nat Struct Mol Biol. 2010;17(5):635-640.
80. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14(4):261-278.
81. Li W, et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A. 2011;108(20):8299-8304.
82. Dey A, Wong E, Kua N, Teo HL, Tergaonkar V, Lane D. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008;7(23):3759-3767.
83. Rio DC. Northern blots for small RNAs and microRNAs. Cold Spring Harb Protoc. 2014;2014(7):793-797.
84. Shin EM, et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest. 2014;124(9):3807-3824.
85. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
86. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
87. Ramirez F, Dundar F, Diehl S, Gruning BA, Manke T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 2014;42(Web Server issue):W187-W191.
88. Alla RK, Cairns BR. RNA polymerase III transcriptomes in human embryonic stem cells and induced pluripotent stem cells, and relationships with pluripotency transcription factors. PLoS One. 2014;9(1):e85648.